



GoldenTree Asset Management

Presentation to SBCERA



	Page #
Firm Overview	3
SBCERA & GoldenTree Relationship Overview	7
Market Outlook & Opportunities	П
Appendix	27

Notes This material contains confidential and/or privileged information. If you are not the intended recipient, please notify the sender immediately and destroy these contents. Any unauthorized copying, disclosure or distribution of this material is strictly prohibited. This material is for information purposes only and is not an offer to sell or a solicitation of any offer to buy shares or interests in a fund. Such offer or solicitation may be made only by the current Offering Memorandum. Accordingly, in regard to any fund products noted within this presentation, please see the Offering Memorandum for complete terms and conditions as available. The net returns noted herein include all components of net income, including investment management fees, incentive fees and special allocations. Past performance is no guarantee and is not indicative of future performance. This performance information is being provided as a supplement to our GIPS® composite returns. Please see schedule(s) for composite information. Please refer to the pages entitled Notes and Legal Disclosures when reviewing performance. Transactions of the type described herein may involve a high degree of risk, and the value of such instruments may be highly volatile. Such risks may include, without limitation, risk of adverse or unanticipated market developments, risk of counterparty or issuer default and risk of illiquidity. To that end, Investors may lose their entire investment. This brief statement does not disclose all the risks and other significant aspects of the transactions of the type described herein, and investors should ensure that they fully understand the terms of any fund investment, including the relevant risk factors and any legal, tax and accounting considerations applicable to them, prior to investing. The specific investments noted within this presentation have been included for informational purposes only to illustrate the investment process. No assurance can be given that similar opportunities will arise or that the performance of these investments will be typical or representative of any or all future investments associated with GoldenTree. It should not be assumed that these investments or any investments made in the future will be profitable, or will equal the performance of the investments noted here. Transactions of the type described herein may involve a high degree of risk, and the value of such instruments may be highly volatile. The above information represents GoldenTree's internal assumptions and analysis. Accordingly, there can be no guarantee as to the results or accuracy of the information noted above. To that end, investors may lose their entire investment in the Fund. Past performance is not indicative of future results. For further investment selection and pricing information in regard to all past investments made by GoldenTree for the fund(s) referenced herein, please contact GoldenTree's Marketing and Client Development Group.

Firm Overview



Firm Overview



- Founded in 2000 with current assets under management of nearly \$55 billion¹
- Employee owned with 25 partners, of whom nearly 50% have been promoted internally
- 96 investment professionals with on average 15 years' experience
- Headquartered in New York with a global physical presence for nearly 20 years. Offices in West Palm Beach, Charlotte, Newport Beach, Dallas, London, Dublin, Munich, Dubai, Singapore, Tokyo and Sydney



- Conservative, value oriented, total return philosophy with disciplined capital base
- Proprietary research on over 1,000 issuers
- Rigorous relative value approach using proprietary technology
- Sophisticated, dynamic approach to risk management



- Generated \$33 billion of gross profit cumulatively since inception²
- Our flagship Master Fund has delivered net returns to investors that are top decile over the last 10 years and since inception³
- Launched 17 private equity style funds to capture specific dislocations or more concentrated opportunities, delivering net annualized returns of ~18% on average⁴
- Fixed income offerings have outperformed their benchmarks across market cycles by ~130bps net on average




- Significant investment in infrastructure comprising over 130 employees
- Ability to execute dedicated, customized SMAs and Fund of Ones
- Global Business Development Team providing valuable insight

I. Assets under management as of September I, 2024. 2. Total gross P&L since inception through August 3 I, 2024 and includes all funds and strategies firm-wide which equates to a P&L net of fees of \$25bn 3. As of June 30, 2024 based on a selected group of peers whose strategies are similar to GoldenTree Moster Fund. 4. Average Net IRR across PE style funds as of June 30, 2024. **Past performance is not indicative of future returns.** Future performance results may be materially lower. Performance of investments in securities held in the above noted funds may be volatile and as a result an investment in such securities is speculative and involves a high degree of risk. Returns are impacted by economic conditions which may or may not persist into the future. Average fixed income outperformance based on the Multi-Sector, Value, and Emerging markets Fund outperformance to their respective benchmarks since each fund's inception



Breadth of GoldenTree's Capabilities

Golden Tree has a track record spanning almost 25 years investing across credit sectors. Our steady and deliberate growth is driven by our consistent investment in our team and infrastructure as credit markets have expanded over the last two decades





Executive Committee

GoldenTree has highly experienced investment and management teams

	Industry Experience	Years at GoldenTree
Steven Tananbaum	37	24
Steven Shapiro	32	24
Kathy Sutherland	28	16
Lee Kruter	24	17
Ted Lodge	41	16
Christopher Hayward	32	5
Simon Granger	27	3
Average	32	15

	Industry Experience ^l
Industry Specialists	14
Restructuring & Turnaround	18
Structured Credit	13
Emerging Markets	17
Capital Markets & Origination	18
Trading	16
Risk Analytics	13
Average	15


Investment Team






Long History of Customized Partnership

GoldenTree has worked closely with SBCERA to evolve the arrangement to capture the best risk-adjusted return and exposure profile for SBCERA





GoldenTree has created value by dynamically capturing opportunities across credit markets, generating total net P&L of over \$650mm for SBCERA since inception





GoldenTree aims to consistently deliver returns that are top quartile if not top decile

SBCERA SMA Performance

					Since Inception	on (Dec 2011)
	2024 YTD	2023	2 Year	5 Year	Annualized Relative Since Performance	Sharpe Ratio	Sortino Ratio
SBCERA SMA (Net)	10.74	13.72	14.55	11.83	10.41	I.4x	2.1x
HFRI Relative Value Fixed Income Corporate Index ¹	6.80	10.16	8.03	5.45	5.69 +471 bps	0.8x	1.0x
HFRI Event Driven Distressed & Restructuring Index I	7.09	5.57	5.08	5.16	5.60 +480 bps	0.6×	0.8x
S&P / LSTA Leveraged Loan Index	6.54	13.32	11.31	5.74	5.15 +526 bps	0.8×	1.0x
ICE BofAML US High Yield Index	8.03	13.46	12.89	4.55	6.10 +431 bps	0.7x	1.0x

Preliminary as of September 30, 2024 unless otherwise noted. Represents SBCERA's combined SMA across Master, Distressed II, Distressed II Distressed IV and Structured Products VII strategies. Results reported herein are preliminary and unaudited, and are subject to change. Final results will differ from the above noted preliminary number.

1. HFRI Indices are asset-weighted and as of August 31, 2024.

Past performance is not indicative of future returns. Future performance results may be materially lower. Performance of investments in securities held in the above noted funds may be volatile and as a result an investment in such securities is speculative and involves a high degree of risk. The net return includes all components of net income, including investment management fees, incentive fees and special allocations. Not an offer to sell or a solicitation of any offer to buy shares or interests in a fund. Further data is available upon request. Neither benchmarks by itself, is an exact representation of SBCERA's portfolio. SBCERA utilizes a multi-strategy style that invests in a variety of securities and products.



Notes

Certain pages contain current market views, opinions, and/or expectations of GoldenTree based on its historic experience and proprietary research, as well as data from third-party sources, as identified herein. This information may not take into account all relevant considerations, may contain elements of subjectivity, or may be based on assumptions that turn out to be incorrect. Such information is subject to change and should not be relied on when making an investment decision.



Something Had to Give - And It Did

The market began 2024 expecting for there to be: I) six rate cuts 2) GDP growth of over 1% and 3) unemployment at 4%. Expectations have since decreased to less than two rate cuts, which we believe is a more reasonable scenario

Key Economic Factors During Easing Cycles

			At First	Rate Cut
Period	Total Reduction in Fed Funds Rate	Peak Unemployment Rate	Real GDPYoY (Four Quarter Avg.)	Fed Funds Rate minus Inflation Expectations
1991-1994	5.00%	7%	0.2%	4.6%
1995-1997	0.50%	6%	2.9%	4.3%
1998-1999	0.75%	5%	4.5%	4.6%
2001-2004	5.50%	6%	1.7%	4.6%
2007-2008	5.00%	6%	2.0%	2.7%
2019	0.75%	4%	2.3%	0.9%
2020	1.50%	15%	-1.1%	1.1%
Median	1.50%	6%	2.0%	4.3%
Fed Forecast (2024-2026)	2.30%	4%	1.9%	3.2%
Current	-	4%	1 .9 %	3.4%

Source: (FRED) St. Louis Fed Economic Data, BLS Data and Goldman Sachs. Fed Forecast is Federal Reserve Summary of Economic Projections as of June 12, 2024. Real GDP (YoY)% represents the four-quarter average of Real GDP (YoY)% for the quarter during the period when the Fed first cut the target funds rate, the prior quarter, and the following two quarters. Peak unemployment rate represents peak +/- one year from the first rate cut at each respective period. Real Fed Funds Rate represents Nominal Fed Funds minus year-ahead inflation expectations, one-year inflation swaps are used since 2006 and Michigan inflation expectations rescaled to the level and standard deviation of break-evens are used prior to 2005. Factor for Rate Cut: Fed Funds Rate Minus Inflation Expectations at 3% or greater, GDP at less than 1% or Unemployment at 6% or greater. Current indicators are Bloomberg Consensus Forecast Expectations as of July 26, 2024.

Valuations Across Credit Asset Classes

Top quartile, which illustrates the most attractive valuations, is reflected when the percentile is below 25%. Bottom quartile is 75% or higher

Valuations Across Credit Asset Classes: Historical Percentiles

		US		E	JR	E	М	U	S
	HY	Loans	IG	НҮ	Loans	IG	HY	CLO A	RMBS
Spreads	90%	57%	87%	79%	57%	91%	27%	89%	45%
Yields	67%	17%	50%	64%	23%	47%	21%	24%	24%
Prices	43%	61%	14%	48%	52%	11%	19%	96%	56%

As of September 27, 2024. 0th percentile represents most attractive valuation since inception and 100th percentile represents least attractive valuation since inception. Source: Bloomberg, Datastream, JPMAM. US High Yield based on daily spreads and yields of ICE BofA US Corporate Index; and US Loans based on monthly spreads of S&P LSTA Index. 3 year discounted spread and monthly yields of S&P LSTA Index. US CLO A based on daily spreads and yields of JPM CLOIE A Index. European Loans based on monthly spreads of S&P ELLI Index. 3 year discounted spread and monthly yields of S&P ELLI Index and yields of JCE BofA European High Yield Index. European High Yield Index European High Yield Index. Europe High Yield Index. But posed on daily spreads and yields of JPM EMBI Global Diversified Index. Rankings based on percentile of all data points up until the date indicated. US HY and HG data begins in 1996, US Loans in 1999, Euro HY in 1997, Euro Loans in 2003, EM IG and HY Debt in 2002 and US CLO A in 2011.



Broad Playbook Creates Opportunities

Capitalizing on various themes across market cycles to capture the most attractive risk-return

Capturing Themes Across Cycles Opportunistic Credit Distressed Private Credit Structured Credit 2020 2021 2022 2023 2024 **Period** Market & Economic **Tightening Financial** Banking Crisis / Market Volatility / **Pandemic Dislocation** Recovery Conditions Recession Risk **Economic Uncertainty** Bank Forced **Technology** Distressed Capital Rate Cut **Cyclicals** Sellers **LBOs** Relief **Beneficiaries Theme** Oil European US Special **Services** Bank Utilities Situations **LMEs** ATIS **Bespoke RMBS** CRT **ABS** and **Example HEXION CMBS Global Medical** Superior



Capitalizing on Current Market Dynamics

GoldenTree is well-positioned to capture near-term themes across asset class

Broad and Compelling Opportunity Set

	Distressed	Private Credit	Structured Credit	Opportunistic Credit
Theme	Strong operating profiles with right sized balance sheets	Proprietary opportunistic financings	Banks seeking capital relief or new origination capacity	Liability management transactions Disrupted sectors
Example	endo.	▲ alvotech Travelodge	Credit Risk Transfer Bespoke ABS	Global Medical Response. desh.





Loans vs. HY Bonds:

Double the Default Rate with Similar Recoveries

While historically HY bonds and loans have experienced similar default rates, when including liability management transactions recent loan default rates exceed HY bond default rates by nearly 200bps









Higher Rates Have Created a Hidden Asset


The hidden asset is liabilities trading at a significant discount


Uptiering ™TriMark® Serta **Mitel** BOARDRIDERS. **TPC** Group incora **Wesco Aircraft**





Liability Management: Often Just a Band-Aid









Amend and extend solution alongside significant sponsor equity created attractive investment opportunity

Substantial Equity Value

\$1.5 bn of Sponsor Equity Value

~\$900mm EBITDA and ~\$5bn+ Revenue

2025 Maturity

Improved Credit Profile

	Before (\$bn)	After (\$bn)
I st Lien Debt	4.8	4.5
2 nd Lien Debt	0.6	-
Total Net Debt	5.4	4.5
Preferred Equity (Converted from 2 nd Lien)	-	0.6
Preferred Equity (Contributed from Sponsor)	-	0.3

AWin-Win Solution

Sponsor

- Three Year Maturity Extension
- \$100mm Annual Cash Interest Savings

Creditors



\$300mm of sponsor equity contributed



125bps coupon increase and lpt OID



Ratings Upgrade and Tighter Covenants



Capitalizing on multiple themes to source and execute attractive opportunities

Overview of Recent Private Credit Investments¹

3.7x
AvgAsset Coverage

I 2% Avg Yield ~\$375 million Avg EBITDA

Providing a Broad Range of Solutions


Use of Proceeds	Theme	Sample Transactions
General Corporate Purposes	 Creating enhanced liquidity and balance sheet flexibility 	HEXION CLUBCORP
Dividend Recap	Facilitating return of capital to investors	· : Recorded SPECIALTIES GLOBAL GLOBAL
Refinancing	 Providing refinancing solutions for companies achieving operational milestones 	Lipton 🔥 alvotech
Acquisition	 Value-enhancing strategic acquisitions 	KnitWell Travelodge
LBO	 Companies with accelerating EBITDA 	alteryx
Restructuring & Turnaround Funding	Proprietary opportunities in GoldenTree-led turnarounds	CELSA GROUP

The specific investment examples noted herein are for informational purposes only. No assurance can be given that similar opportunities will arise or that the performance of these investments will be typical or representative of any or all future investments associated with GoldenTree. It should not be assumed that these investments or any investments made in the future will be profitable. I. Includes all private credit investments made during 2024 as of June 30, 2024. Reflects characteristics at close.



Capitalizing on Shifting Opportunity Set

GoldenTree's ability to structure a broad range of solutions enables it to selectively target investments with compelling return profiles as the opportunity set shifts







Alvotech is a global biotech company that specializes in the development and manufacturing of high-quality biosimilar medicines

Investment

Ist Lien Term Loan **Price** \$96 Yield 12% Coupon S+650 Asset 5.0x Coverage Call \$103 **Protection** Term 5 years

Investment Details

- Alvotech develops and manufactures biosimilar medicines, which offer cost-effective treatment options, for autoimmune and inflammatory diseases
- The company has obtained approval in major markets for its first two products and has a diverse pipeline of nine additional biosimilars
- Alvotech benefits from long-term agreements with established pharmaceutical market participants, driving milestone payments which create steady cash flow
- GoldenTree's significant pharma experience, engagement with management, and ability to underwrite the business quickly and in size created a proprietary opportunity
- The Ist lien transaction presents a compelling risk-return profile:
 - High margin of safety with 5x asset coverage provides for an LTV of 20%
 - Attractive OID, coupon and call protection creates a total return profile of 15%+
 - Secured strong covenants including minimum liquidity requirements, minimal RP/incremental Ist lien debt limits, and protection against affiliate transactions
- Over the coming years, we expect the company to generate strong EBITDA growth and attractive FCF, enabling it to secure cheaper financing in the public market

I. Represents metrics at close. Call protection refers to I spear call protection price after a one-year non-call period. The above information is based on GoldenTree's internal assumptions and analysis based in part on the current market environment. Accordingly, there can be no guarantee as to the results or accuracy of the information noted above. Assumptions and projections are necessarily speculative in nature, and it can be expected that some or all of the underlying assumptions will not materialize or will vary significantly from actual results, and such variations may be material. This is not a promise of future performance. No assurance can be given that similar opportunities will arise or that the performance of this investment will be typical or representative of any or all future investments associated with GoldenTree.





Alvotech's complex earnings profile allowed GoldenTree to structure an attractive solution for the company, which benefits from high barriers to entry and broad in-house capabilities

	Key Drivers for Private Transaction
Factor	GoldenTree Advantage vs. Traditional Lenders
Unrated	Unlike CLOs which cannot participate in unrated transactions, GoldenTree neither requires a public rating nor relies on one to evaluate an investment's margin of safety
Complex Earnings Profile	While Alvotech's negative trailing 12-month EBITDA did not fit the leveraged lending guidelines of banks, GoldenTree had the resources and expertise to model the company's forward earnings profile
Mutual Partnership	GoldenTree's engagement with management combined with its proprietary analysis enabled us to structure the most optimal solution for the company's unique situation

Overview of Biosimilars

- Biosimilars, whose high complexity limits competition, are medicines that are nearly identical to existing biologics already approved by the FDA
- Biosimilars are approved upon the basis of demonstrating no clinically meaningful differences in terms of quality, efficacy, and safety compared with a reference biologic

Alvotech's Integrated Approach



Purpose-built and in-house R&D platform with rigorous quality-focus



Single-use technology within state-ofthe-art manufacturing facility



Broad network of strategic partnerships to provide global reach and leverage local expertise



Multiple Themes Across Structured Credit

Regulatory constraints are driving banks to engage in risk transfer transactions to optimize their balance sheets Bank **ABS** Capital Relief GoldenTree well positioned to continue to source proprietary transactions and create bespoke solutions that generate strong risk adjusted returns Capital market volatility can drive dislocations in the liquid structured credit market, creating opportunities to source opportunities at deep discounts **Liquid Market CRT RMBS Opportunities** GoldenTree has demonstrated a track record of capitalizing on market / CLOs volatility such as the LDI crisis in 2H 2022 and the pandemic in March 2020 Identified idiosyncratic, event-driven situations in opportunities that we believe create strong risk adjusted returns **Event Driven CLOs** Examples includes issues that we expect to get upgraded, refinanced at a call premium or other near-term catalyst to drive total return We expect dislocations in CMBS to accelerate given the macroeconomic environment **CMBS SASB** We have identified opportunities across various structures such as SASB Volatility and more limited market liquidity has created opportunities in new issue ABS New Issue ABS **ABS** Opportunities are broad based across collateral type such as corporate, residential and higher-quality consumer assets



Opportunities in SRT/CRT Transactions

Bank capital is under increased pressure. Credit Risk Transfer (CRT) transactions provide an attractive solution to optimize RWA, increase capital ratios, and enhance bank returns, driving an addressable market of ~ \$1.5T of assets for securitization

Pressures on Bank Capital US Regional Bank CE

Higher Interest Rates

- Higher rates have driven losses in bank securities holdings and require higher credit reserves for interest-sensitive asset types
- Banks with over \$10 billion of assets have estimated MTM losses of ~19% of their Tier 1 capital at current rates

Regulatory Changes

- Basel III Endgame (B3E) and other proposed regulatory reform will increase capital requirements
- Even with a softening of current B3E proposal, US Regional banks have a ~150-200 bps Tier I capital shortfall
- This implies banks will need to build capital and optimize RWAs by ~20%

US Regiona	al Bank CETTI	Katios'
	4Q 2023	2Q 2024
Reported CETI Ratio	10.7%	11.2%
CETI Ratio Adjusted for AOCI	8.5%	9.1%
Decline in CETI Ratios	~220 bps	~210 bps



Barclays Credit Risk Transfer Transaction

Sourced and structured exclusive transaction providing capital solution for Barclays and differentiated investment for GoldenTree investors

Attractive Risk-Return vs. CLOs & RN

Attractive Risk-Return vs. CLOs & RMBS			
	BBB US CLO Debt	BBB RMBS	Barclays Credit Risk Transfer
Yield	8%	6%	15%
Breakeven Default	15%	5%	6%
Multiple of Peak Default	2x	3×	3×
Target Return	9 %	10%	20%

Mortgage Pool Characteristics

3 -0	
Size	€4.I billion
Туре	I st lien, fully amortizing
Average LTV	45%
Average Seasoning	l 4 years
Historical Delinquencies	1%

Based on data as of transaction close on April 18, 2024.

Appendix





Kathy SutherlandPartner & Chief Executive Officer

Kathy Sutherland is a Partner and the Chief Executive Officer of GoldenTree Asset Management. In addition, Ms. Sutherland isa member of GoldenTree's Executive Committee. Ms. Sutherland oversees the firm's global strategy, product and business development, and long-term planning. Prior to joining GoldenTree, Ms. Sutherland was a Managing Director at J.P. Morgan where she was responsible for Fund and Structured Credit Distribution across the Americas, Europe, the Middle East, and Asia from 2005 to 2008. During that period, J.P. Morgan became recognized as a leading Fund and Structured Credit franchise, advising many of the most important asset managers and investors globally. In her 12 years at J.P. Morgan, Ms. Sutherland held several management positions across Portfolio Management, Structured Credit and High Yield including Senior US CLO Structurer, Co-Head of European Secondary Loan Trading, Head of High Yield Credit Derivatives Marketing, and Global Head of Structured Syndicate. Ms Sutherland graduated from the University of Virginia with a B.A. in Chemistry and specialization in Biochemistry. She currenty serves on the Board of Directors of the Susan G. Komen Foundation.



Lee KruterPartner & Head of Performing Credit

Lee Kruter is a Partner and Head of Performing Credit at GoldenTree Asset Management. Mr. Kruter is the Lead Portfolio Manager for the Multi-Sector strategy, GoldenTree Loan Management and the firm's Corporate Credit and fixed income oriented Structured Credit strategies. Mr. Kruter is a member of GoldenTree Asset Management's Executive Committee and GoldenTree's Private Credit Committee. Mr. Kruter's leadership has been instrumental in the performance and growth of the firm's fixed income offerings. Prior to joining GoldenTree, Mr. Kruter was a Vice President at Credit Suisse and spent seven years in the Leveraged Finance Research group, where he was responsible for the healthcare and services sectors. During his time at Credit Suisse, Mr. Kruter also covered various other sectors including metals & mining and wireless & wireline telecommunications. Mr. Kruter holds a B.S. in Finance and Management Information Systems from New York University's Leonard N. Stern School of Business. Mr. Kruter is also a CFA charterholder.

Past performance is not indicative of future results. Future performance results may be materially lower. Performance of investments in the securities described herein may be volatile and as a result an investment in such securities is speculative and involves a high degree of risk. The net returns noted herein include all components of net income, including investment management fees, incentive fees and special allocations. This performance information is being provided as a supplement to the GIPS® composite returns which is included herein. The examples of investment themes, strategies and representative investments noted within the presentation have been included for informational purposes only. No assurance can be given that similar opportunities will arise or that the performance of these investments will be typical or representative of any or all future investments associated with GoldenTree. Accordingly, it should not be assumed that investments made in the future will be profitable or will equal the performance of the investments referenced within this presentation. For further information regarding the performance of past investments purchased/sold by GoldenTree during the prior twelve months, with respect to its managed accounts/funds, please contact GoldenTree's Business Development Group. All information and any forward-looking statements contained herein are based on GoldenTree's expectations and assumptions as of the date noted in this presentation and is subject to change without notice.

AUM figures represent total capital committed and include assets managed by GoldenTree Loan Management, LP, an affiliated US based registered investment adviser. With respect to CLO vehicles, total assets include the effects of leverage and all available capital to invest.

The private funds referred to in this presentation have not been registered under the securities laws of any jurisdiction. This material is for informational purposes only and is not an offer to sell or a solicitation of any offer to buy shares or interests in a fund. Such offer or solicitation will be made only through the applicable Private Offering Memorandum and subscription application, and is qualified in its entirety by the terms and conditions contained in such documents. Each Private Offering Memorandum contains additional information needed to evaluate an investment in a fund and provides important disclosures, including, but limited to, disclosures regarding risks, fees and expenses. Examples of certain risk factors associated with an investment in a private fund may include the following:

Loss of all or a substantial portion of an investment due to leveraging, short-selling and investing in speculative securities. Lack of liquidity in that there is generally no secondary market for an investor's interests in a non-registered private fund. Volatility of returns.

Restrictions on transferring an investor's interest in the fund. Absence of information regarding pricing and valuations.

Delays in tax reporting.

Less regulation and higher fees than mutual funds.

Net IRR uses the present sum of cash contributed, the sum of distributions, and the current value of unrealized investments and applies a discount. This amount is net of any carry/performance fees earned by the GP.

Accordingly, before making an investment in a private fund, potential investors should carefully read the applicable Private Offering Memorandum and subscription application and consult their professional advisor as an investment in a private fund is speculative, not appropriate for all clients, and is intended for experienced and sophisticated investors who are willing to bear the high risks of such an investment.

This material contains confidential and/or privileged information. Any unauthorized copying, disclosure or distribution of this material without the express written consent of GoldenTree Asset Management, LP is strictly prohibited.

GoldenTree Asset Management GmbH

GoldenTree Asset Management GmbH ("Tied Agent") is a tied agent within the meaning of Article 29 (3) of Directive 2014/65/EU ("MiFID II" as implemented in the respective national legislation) of Acolin Europe AG, which is authorised and regulated by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). The Tied Agent is entered in the public register of tied agents held by BaFin.

Only within the scope of providing financial services ("investment brokerage" within the meaning of Annex I A (I) MiFID II as implemented in the respective national legislation by promotion of the potential investor's willingness to enter into a transaction but excluding the reception and transmission of orders in relation to one or more financial instruments), the Tied Agent acts exclusively on behalf and for the account of Acolin Europe AG and undertakes to exclusively distribute GoldenTree funds.

The information provided by the Tied Agent is intended for informational purposes only and does not represent an offer to purchase or sell financial instruments. All information is provided without any guarantee. This information neither represents any investment / legal / tax advice, nor any recommendation. The Agent points out that every investment decision should be made after consulting an advisor. The information is intended exclusively for professional clients within the meaning of Annex II MiFID II. The information provided may not be copied or further distributed to third parties without the prior consent of Acolin Europe AG. The information may not be given to persons or companies that do not have their ordinary residence or domicile in the countries in which Acolin Europe AG is authorized to provide financial services. In particular, the information may not be made available to US citizens or persons residing in the USA.